According to Merck's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 17.5025. At the end of 2021 the company had a P/E ratio of 14.8.
Year | P/E ratio | Change |
---|---|---|
2021 | 14.8 | -49.27% |
2020 | 29.2 | 29.47% |
2019 | 22.6 | -27.17% |
2018 | 31.0 | -45.92% |
2017 | 57.4 | 110.42% |
2016 | 27.3 | -14.4% |
2015 | 31.8 | 144.67% |
2014 | 13.0 | -59.55% |
2013 | 32.2 | 79.31% |
2012 | 17.9 | 1.85% |
2011 | 17.6 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 21.1 | 20.63% | ๐บ๐ธ USA |
![]() Novartis NVS | 8.55 | -51.17% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 7.66 | -56.25% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | 22.9 | 30.83% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 49.3 | 181.86% | ๐บ๐ธ USA |
![]() Amgen AMGN | 18.6 | 6.14% | ๐บ๐ธ USA |
![]() Sanofi SNY | 14.7 | -15.85% | ๐ซ๐ท France |
![]() Bristol-Myers Squibb BMY | 21.6 | 23.56% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 4.22 | -75.87% | ๐ฌ๐ง UK |
![]() Teva Pharmaceutical Industries TEVA | -7.59 | -143.34% | ๐ฎ๐ฑ Israel |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.